Fuchs endothelial corneal dystrophy: current perspectives

Area of Science:

• Ophthalmology
• Genetics
• Cell Biology

Background:

• Fuchs endothelial corneal dystrophy (FECD) is the most prevalent corneal dystrophy, often leading to significant vision impairment.
• Key pathological features include corneal endothelial cell loss and abnormal Descemet's membrane excrescences, progressing to affect all corneal layers.
• Disease progression is driven by endothelial barrier and pump dysfunction, alongside cell death induced by oxidative and unfolded protein stress.

Purpose of the Study:

• To provide a comprehensive overview of current knowledge regarding FECD.
• To highlight recent advancements in understanding the clinical presentation, underlying pathophysiology, and genetic basis of FECD.
• To discuss emerging treatments, including updated endothelial keratoplasty techniques and potential future therapeutic strategies.

Main Methods:

• Literature review of clinical, pathological, genetic, and therapeutic research on FECD.
• Analysis of recent studies on endothelial keratoplasty outcomes.
• Synthesis of findings on the genetic factors, particularly TCF4 gene alterations, implicated in FECD.

Main Results:

• FECD involves progressive endothelial cell loss and structural corneal changes.
• Genetic factors, notably the transcription factor 4 (TCF4) gene, play a significant role in the majority of FECD cases.
• Endothelial keratoplasty represents the current gold standard for definitive FECD treatment, with ongoing refinements.

Conclusions:

• Significant progress has been made in elucidating the complex mechanisms driving FECD.
• Understanding the genetic underpinnings and cellular stresses is crucial for developing targeted therapies.
• Continued research into novel treatments and surgical techniques promises to improve outcomes for patients with FECD.